Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study

2019· article· en· 340 citations· W2908242089 sur OpenAlex· 10.1016/j.jpsychires.2019.01.003

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Organisme subventionnaire canadienUn organisme canadien l'a financé. Le travail peut ne porter aucune affiliation canadienne.

Aucune affiliation canadienne. Une base fondée sur la seule affiliation (le devis habituel) n'aurait jamais vu ce travail. C'est l'un des travaux qui justifient l'inversion de la base.

Scores machine (provisoires)

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Tête enseignante Opus0,090

Tête enseignante GPT0,507

Écart entre enseignants: 0,417 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validation: score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Résumé

Current prescribing practices for major depressive disorder (MDD) produce limited treatment success. Although pharmacogenomics may improve outcomes by identifying genetically inappropriate medications, studies to date were limited in scope. Outpatients (N = 1167) diagnosed with MDD and with a patient- or clinician-reported inadequate response to at least one antidepressant were enrolled in the Genomics Used to Improve DEpression Decisions (GUIDED) trial - a rater- and patient-blind randomized controlled trial. Patients were randomized to treatment as usual (TAU) or a pharmacogenomics-guided intervention arm in which clinicians had access to a pharmacogenomic test report to inform medication selections (guided-care). Medications were considered congruent ('use as directed' or 'use with caution' test categories) or incongruent ('use with increased caution and with more frequent monitoring' test category) with test results. Unblinding occurred after week 8. Primary outcome was symptom improvement [change in 17-item Hamilton Depression Rating Scale (HAM-D17)] at week 8; secondary outcomes were response (≥50% decrease in HAM-D17) and remission (HAM-D17 ≤ 7) at week 8. At week 8, symptom improvement for guided-care was not significantly different than TAU (27.2% versus 24.4%, p = 0.107); however, improvements in response (26.0% versus 19.9%, p = 0.013) and remission (15.3% versus 10.1%, p = 0.007) were statistically significant. Patients taking incongruent medications prior to baseline who switched to congruent medications by week 8 experienced greater symptom improvement (33.5% versus 21.1%, p = 0.002), response (28.5% versus 16.7%, p = 0.036), and remission (21.5% versus 8.5%, p = 0.007) compared to those remaining incongruent. Pharmacogenomic testing did not significantly improve mean symptoms but did significantly improve response and remission rates for difficult-to-treat depression patients over standard of care (ClinicalTrials.gov NCT02109939).

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

La notice

Revue: Journal of Psychiatric Research
Thématique: Treatment of Major Depression
Domaine: Medicine
Établissements canadiens: —
Organismes subventionnaires: Fusion Oriented REsearch for disruptive Science and TechnologyJanssen BiotechCanadian Institutes of Health ResearchAgency for Healthcare Research and QualityAllerganNational Institutes of HealthRogers Family FoundationAssurex HealthNational Institute of Mental HealthPfizerLivaNovaOntario Brain InstitutePatient-Centered Outcomes Research InstituteAvanir PharmaceuticalsStanley Medical Research InstituteACADIA PharmaceuticalsAlkermesAcadia UniversityBristol-Myers SquibbOtsuka AmericaBiogen
Mots-clés: MedicineRandomized controlled trialMajor depressive disorderPharmacogenomicsDepression (economics)Hamilton Rating Scale for DepressionRating scaleClinical trialInternal medicinePsychiatryPhysical therapyPsychologyMoodPharmacology
Résumé présent dans OpenAlex: oui
API: /api/v1/works/W2908242089